Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

94 results about "Bacillus enteritidis" patented technology

Method and composition for reducing E. coli disease and enhancing performance

Bacillus strains that inhibit pathogenic swine E. coli and / or improve performance are provided. Inhibition of pathogenic swine E. coli decreases E. coli disease. At least one strain enhanced swine performance by improving average daily gain, feed efficiency, and feed intake. Preferred Bacillus strains are of species that are included on the GRAS list. Bacillus species are sporeformers and therefore are highly stable and can be fed to swine.
Owner:AGTECH PRODS

Escherichia coli-bacillus subtilis shuttle expression vector and application thereof

ActiveCN102002509AStrong ability to secrete extracellular proteinsFungiBacteriaAspergillus nidulansGenetic engineering
The invention discloses an Escherichia coli-bacillus subtilis shuttle expression vector and application thereof, and belongs to the field of genetic engineering. The Escherichia coli-bacillus subtilis shuttle expression vector comprises a bacillus subtilis promoter sequence, a bacillus subtilis signal peptide coding sequence, an artificially designed ribosome binding sequence which can be identified by bacillus subtilis, the artificially designed enzyme cutting site of bacillus subtilis signal peptidase, an artificially designed multiple cloning site, a bacteriophage terminator sequence, a bacillus subtilis replicating initial sequence, and an Escherichia coli replicating initial sequence. The vector can be replicated in Escherichia coli and can also be replicated and expressed in the bacillus subtilis, so that vectors for a bacillus subtilis expression system are enriched; and the vector uses a B.subtilis deacetylated chitinase signal peptide for the first time, the signal peptide has high capability of guiding to secrete extracellular protein, a reporter gene is aspergillus nidulans pectate lyase gene, and the extracellular expression level reaches 600U / mL which is higher than that when the pectate lyase gene uses other vectors.
Owner:JIANGNAN UNIV

Recombinant escherichia coli for heterologously synthesizing ambrein and construction method thereof

The invention discloses recombinant escherichia coli for heterologously synthesizing ambrein and a construction method thereof. The construction method comprises the following steps of: (1) fusing saccharomyces-cerevisiae squalene synthase gene ERG9 with truncation of 26 amino acid residues at a C end and homologous arms at the upstream and downstream of a lacZ site of the escherichia coli into adonor DNA; constructing plasmid 1; transforming the donor DNA and the plasmid 1 together into the escherichia coli, eliminating the plasmid 1, obtaining the recombinant escherichia coli for synthesizing squalene, and naming the recombinant escherichia coli as a strain 1; (2) connecting alicyclobacillus-acidocardarius squalene-hopene cyclase gene D377C SHC with mutation from the 377th amino acid residue into cysteine residue and bacillus-megaterium cyclase gene BmeTC into one segment, then inserting the segment into escherichia-coli expression plasmid p5C to obtain plasmid 4; (3) transforming the plasmid 4 into the strain 1 to obtain the recombinant escherichia coli for heterologously synthesizing the ambrein, and naming the recombinant escherichia coli as a strain 4. Proved by experiments,the recombinant escherichia coli for heterologously synthesizing the ambrein is fermented to obtain the ambrein.
Owner:TIANJIN UNIV

Hylarana guentheri antibacterial peptide and application thereof

The invention relates to sequences, a preparation method and application of two types of hylarana guentheri antibacterial peptides. The two types of antibacterial peptides are separated from skin secreta of hylarana guentheri, and antibacterial and hemolytic activities of the antibacterial peptides are detected; a secondary structure of the antibacterial peptides under a simulated film environment is researched. The two antibacterial peptides are obtained: the antibacterial peptide A with an amino acid sequence shown as SEQ ID NO.1; the antibacterial peptide B with an amino acid sequence shown as SEQ ID NO.2. The antibacterial peptide A provided by the invention has an inhibition effect on staphylococcus aureus, colon bacillus and bacillus subtilis; the antibacterial peptide B has a very good sterilization effect on the bacillus subtilis and the staphylococcus aureus. The two types of antibacterial peptides, provided by the invention, have the characteristics of novel structure, strong antibacterial activities and the like, and have an important value in the aspects of medicine development and application. The sequences, the preparation method and the application of two types of the hylarana guentheri antibacterial peptides have important meanings on researches of an antibacterial mechanism of the antibacterial peptides, and further improvement, and development and utilization of the antibacterial peptides.
Owner:FUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products